遭法律诉讼威胁，Hims & Hers下架仿版减肥药物

Core Viewpoint - Hims & Hers has decided to withdraw its generic weight loss drug from the market following legal threats from Novo Nordisk and the FDA's announcement of potential legal action against the company [2][6]. Group 1: Product Withdrawal - Hims & Hers announced the withdrawal of its generic drug containing semaglutide, which was initially priced at $49 for the first month, significantly lower than Novo Nordisk's original product priced about $100 higher [2][6]. - The company stated that it has engaged in constructive communication with industry stakeholders since the launch of the semaglutide formulation [2][6]. Group 2: Legal Threats - Novo Nordisk threatened legal action against Hims & Hers, accusing the company of "illegally compounding drugs in bulk" and misleading the public with its generic GLP-1 product [2][6]. - The FDA plans to take legal action against Hims & Hers, which includes restricting access to the drug's raw materials and referring the case to the Department of Justice [2][6]. Group 3: Company Response - Hims & Hers responded by asserting its commitment to consumer safety and compliance with current laws and regulations [3][7]. - The company had planned to air an advertisement during the Super Bowl, highlighting the health gap in America, but made the decision to withdraw the drug just before the event [3][7].